Jeffrey L. Cummings, MD, ScD, The University of Nevada, Reno, NV, provides an overview of his presentation at the AD/PD 2021 conference analyzing the Alzheimer’s disease (AD) therapeutic pipeline, which indicated that there is a significant focus on disease-modifying therapies and a growing diversification in the pipeline with rising trends in the study of tau protein, inflammation and synaptic protection. He also describes some highlights from the AD/PD symposium on the role of amyloid-beta in the pathophysiology of AD, which covered the genetics, biomarkers and clearance of amyloid-beta. This interview took place during the AD/PD™ 2021 conference.

свернуть